Tirbanibulin

KLISYRI

What it isA topical microtubule inhibitor ointment for actinic keratosis of the face and scalp.

Why this oneThe regimen is its selling point: once daily for five days, against weeks of irritation with older field therapies.

What limits itExpect a brief local reaction, and recurrence over time — field cancerization is managed, not cured.

FDA label

FDA dosing	Population	Start	Target	Max
Actinic keratosis of the face or scalp	Adults	Topical: apply QD to treatment field (up to 100 cm2) on face or balding scalp, 1 unit-dose packet per application	Topical QD x 5 consecutive days (single course)	Topical QD x 5 days; up to 100 cm2 field

Renal Undefined

Hepatic Undefined

Topical use only; not for oral or ophthalmic use
Wash hands immediately with soap and water after application
Avoid washing or touching the treated area for ~8 h after application; afterwards may wash with mild soap
Avoid transfer to periocular area; avoid application near mouth and lips
Avoid use until skin has healed from any previous drug, procedure, or surgical treatment
Occlusion after application increases irritation

Ophthalmic adverse reactions: eye irritation on accidental ocular exposure — flush with water and seek medical care
Local skin reactions, including severe (vesiculation/pustulation, erosion/ulceration), in the treated area

Local skin reactions: erythema (91%), flaking/scaling, crusting, swelling
Application site pain (10%)
Application site pruritus (9%)
No contact sensitization, phototoxicity, or photoallergy in dermal safety studies

Pregnancy No human data; oral tirbanibulin in animals caused fetal deaths/malformations at >=19x MRHD exposure

Lactation No data on transfer to human or animal milk; weigh benefits of breastfeeding vs maternal need

NO BOXED WARNINGS